| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf8373f3013dca535a8f1ad5458725f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4a57cd95c9c7e00ec9b777ccb0697904 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-70 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2845
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-241
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08 |
| filingDate |
2010-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bef38ded732ed4f3f02674769386fe56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32d52d0c11502c3552fd9ded0fc9f186
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77b70e49fbb5ce5571d58c20fbc4a9cf |
| publicationDate |
2012-04-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2444101-A1 |
| titleOfInvention |
Selective targeting of the CD40L/Mac-1 interaction by small peptide inhibitors and its use for the treatment of inflammation and atherogenesis |
| abstract |
The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3260133-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2017220369-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019161550-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10919967-B2 |
| priorityDate |
2010-10-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |